State Street
PRLD icon

State Street’s Prelude Therapeutics PRLD Stock Holding History

State Street’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$473K Buy
138,231
+10,939
+9% +$28.7K ﹤0.01% 3670
2025
Q4 		$369K Buy
127,292
+29,700
+30% +$50.1K ﹤0.01% 3757
2025
Q3 		$141K Hold
97,592
– – ﹤0.01% 3987
2025
Q2 		$79K Sell
97,592
-188,454
-66% -$163K ﹤0.01% 4017
2025
Q1 		$220K Sell
286,046
-7,350
-3% -$6.86K ﹤0.01% 3798
2024
Q4 		$374K Buy
293,396
+7,350
+3% +$9.75K ﹤0.01% 3698
2024
Q3 		$592K Buy
286,046
+74,300
+35% +$344K ﹤0.01% 3566
2024
Q2 		$807K Buy
211,746
+305
+0.1% +$1.24K ﹤0.01% 3498
2024
Q1 		$1M Sell
211,441
-793
-0.4% -$3.08K ﹤0.01% 3473
2023
Q4 		$906K Buy
212,234
+25,025
+13% +$76.2K ﹤0.01% 3499
2023
Q3 		$578K Buy
187,209
+3,400
+2% +$12.8K ﹤0.01% 3635
2023
Q2 		$827K Buy
183,809
+139,920
+319% +$836K ﹤0.01% 3611
2023
Q1 		$250K Hold
43,889
– – ﹤0.01% 3983
2022
Q4 		$265K Hold
43,889
– – ﹤0.01% 4004
2022
Q3 		$290K Hold
43,889
– – ﹤0.01% 3978
2022
Q2 		$229K Sell
43,889
-165,972
-79% -$845K ﹤0.01% 4134
2022
Q1 		$1.45M Buy
209,861
+1,455
+0.7% +$13.3K ﹤0.01% 3680
2021
Q4 		$2.6M Sell
208,406
-642,077
-75% -$10.4M ﹤0.01% 3559
2021
Q3 		$26.6M Sell
850,483
-201,733
-19% -$6.53M ﹤0.01% 2273
2021
Q2 		$30.1M Buy
1,052,216
+178,840
+20% +$6.37M ﹤0.01% 2223
2021
Q1 		$37.8M Buy
873,376
+731,043
+514% +$48.5M ﹤0.01% 1949
2020
Q4 		$10.2M Buy
+142,333
New +$7.08M ﹤0.01% 2621

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street's PRLD Position: Q1 2026 in Review

State Street increased its Prelude Therapeutics (PRLD) stake by 8.6% in Q1 2026, buying an estimated $28.7K and bringing the position to 138,231 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #3670.

State Street first reported a position in PRLD in Q4 2020 and has held it in 22 quarters since. The position peaked at $37.8M in Q1 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • State Street held 138,231 shares of Prelude Therapeutics worth $473K as of Q1 2026.
  • State Street bought 10,939 Prelude Therapeutics shares in Q1 2026, an estimated $28.7K.
  • Prelude Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3670 holding.
  • State Street first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • State Street's Prelude Therapeutics position peaked at $37.8M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.